A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

Part of paid clinical trials in Los Alamitos, California.

Sponsor
AbbVie
Study ID
NCT07604558
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Bretisilocin — DRUG
    Intramuscular Injection

Study Details

This study will assess the adverse events, tolerability, and how bretisilocin intramuscular (IM) Injection moves through the body of healthy adult Japanese, Han Chinese, and Non-Asian volunteers participants.

Key Dates

Start date
May 26, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
26 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Group 1-Bretisilocin-Japanese
    Participants will receive bretisilocin intramuscular (IM) injection on day 1.
  • Experimental: Group 1-Bretisilocin-Han Chinese
    Participants will receive bretisilocin intramuscular (IM) injection on day 1.
  • Experimental: Group 1-Bretisilocin-Non-Asian
    Participants will receive bretisilocin intramuscular (IM) injection on day 1.

Primary Outcome Measure

Number of Participants Experiencing Adverse Events [ Time Frame: Up to approximately 32 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel Collaborative Neuroscience Research /ID# 281612Los AlamitosCalifornia90720-

Find similar trials in Los Alamitos, CA

By research site
CenExel Collaborative Neuroscience Research· Los Alamitos, CA

Related Studies